Data / Form D filings / EtiraRX, Inc.
EtiraRX, Inc.: Form D filings
EtiraRX, Inc., a biotechnology company in Dallas, TX, filed 3 Form D notices with the SEC between 2023 and 2026. The latest, on May 14, 2026, reports $2.3 million sold of a $3 million offering to 21 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3060 PEGASUS PARK DRIVE BUILDING 6, Dallas, TX, 75247
- Phone
- (469) 600-6603
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1996442
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | New notice | $3,000,003 | $2,277,533 | $722,470 | 21 | Apr 17, 2026 | sec.gov |
| Jun 23, 2025 | New notice | $4,869,987 | $2,399,987 | $2,470,000 | 3 | Jun 6, 2025 | sec.gov |
| Oct 5, 2023 | New notice | $10,595,149 | $4,820,140 | $5,775,009 | 34 | Sep 15, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Russell Hayward | Executive Officer, Director | |
| Ganesh Raj | Executive Officer, Director | |
| Justin Stebbing | Director | |
| Annalisa Jenkins | Director |
Other biotechnology companies in Texas that filed recently
- Nuclein, LLC $15.7 million · Oct 27, 2026
- OncoNano Medicine, Inc. $10.1 million · Oct 8, 2026
- Solaris Endovascular Inc. $5 million · Oct 1, 2026
- Hera Biotech, Inc. $1.7 million · Sep 23, 2026
- Kayak Therapeutics, Inc. $25 million · Aug 21, 2026
- InnovoTEX Inc. $2.7 million · Aug 18, 2026
Every Form D from the week of May 11, 2026 · All recent filings in Texas · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what EtiraRX, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.